Comparative Pharmacology
Head-to-head clinical analysis: MEGACE versus MEGACE ES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEGACE versus MEGACE ES.
MEGACE vs MEGACE ES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Megestrol acetate is a synthetic progestin that inhibits pituitary gonadotropin secretion, leading to suppression of ovarian function and reduction of sex hormone levels. It also has antineoplastic effects through interference with estrogen receptor binding and may stimulate appetite via effects on neuropeptide Y and cytokines.
Megestrol acetate is a synthetic progestin that inhibits pituitary gonadotropin secretion, leading to suppression of ovarian and testicular hormone production. It also has antineoplastic effects possibly through local action on hormone-sensitive tissues and stimulates appetite via modulation of neuropeptide Y and other appetite-regulating factors.
Oral: 625 mg (suspension) or 400–800 mg (tablets) once daily.
625 mg orally once daily (MEGACE ES suspension contains 625 mg/5 mL; shake well before use). For appetite stimulation in cachexia.
None Documented
None Documented
Terminal elimination half-life: 70-95 hours (mean 85 hours) in chronic dosing; shorter in initial doses; clinical context: requires 3-4 weeks to reach steady state.
Approximately 34 hours in plasma; steady-state achieved after 2-3 weeks of daily dosing.
Primarily renal: ~75% as glucuronide conjugates and unchanged drug; biliary/fecal: ~25% as metabolites.
Primarily renal (≤1% unchanged) and biliary; extensive metabolism to inactive glucuronide conjugates excreted in feces.
Category C
Category C
Progestin
Progestin